EcoDrugPlus

Mitogen-Activated Protein Kinase 8b-Like

Ensembl ID : ENSNBRG00000003479
Gene Symbol: LOC102796928
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSNBRG00000011028
Gene Symbol: MAPK9
3 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSNBRG00000004219
Gene Symbol: MAP3K10
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSNBRG00000011726
Gene Symbol: MAP3K11
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSNBRG00000003808
Gene Symbol: MAP3K12
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12-Like

Ensembl ID : ENSNBRG00000023300
Gene Symbol: LOC102795570
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSNBRG00000016703
Gene Symbol: MAP3K13
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5-Like

Ensembl ID : ENSNBRG00000002912
Gene Symbol: LOC102796575
3 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSNBRG00000013360
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSNBRG00000002091
Gene Symbol: MAP3K9
3 Cross references
193 Possible Orthologues:

Monoglyceride Lipase-Like

Ensembl ID : ENSNBRG00000023224
Gene Symbol: LOC102789958
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSNBRG00000001998
Gene Symbol: MLNR
1 Cross references
174 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).